Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optune, Avastin, and Temodar in Newly Diagnosed Unresectable Glioblastoma
NCT02343549Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2015
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in glioblastoma (GBM), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Participants With 12-Month Survival. Started Jan 2015; status: terminated.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02343549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343549.